Success Metrics

Completion Rate
0%(0/1)
Active Trials
2(67%)
Terminated
1(33%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_1
1
33%
Ph not_applicable
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Terminated(1)

Detailed Status

Terminated1
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
N/A1 (33.3%)

Trials by Status

terminated133%
recruiting133%
active_not_recruiting133%

Recent Activity

2 active trials
Showing 3 of 3
terminatedphase_2

Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

NCT00707473
recruitingnot_applicable

Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial

NCT07188532
active_not_recruitingphase_1

Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

NCT04420975

Clinical Trials (3)

Showing 3 of 3 trials
NCT00707473Phase 2

Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

Terminated
NCT07188532Not Applicable

Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial

Recruiting
NCT04420975Phase 1

Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

Active Not Recruiting

All 3 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
3